|
MARVELD2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.08499999984524E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.68239999998043E-06 |
| Normal-vs-Stage2 |
7.404500E-02 |
| Normal-vs-Stage3 |
1.27520000114956E-08 |
| Normal-vs-Stage4 |
5.44849720895968E-11 |
| Stage1-vs-Stage2 |
4.887600E-02 |
| Stage1-vs-Stage3 |
9.035700E-02 |
| Stage1-vs-Stage4 |
5.564000E-04 |
| Stage2-vs-Stage3 |
9.264900E-03 |
| Stage2-vs-Stage4 |
4.237100E-04 |
| Stage3-vs-Stage4 |
1.259380E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
6.45440001445508E-09 |
| Normal-vs-AfricanAmerican |
8.821900E-03 |
| Normal-vs-Asian |
1.52739999981222E-07 |
| Caucasian-vs-AfricanAmerican |
3.152400E-01 |
| Caucasian-vs-Asian |
6.035200E-01 |
| AfricanAmerican-vs-Asian |
2.693600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.92640000000033E-05 |
| Normal-vs-Female |
4.65339999866643E-09 |
| Male-vs-Female |
4.300200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.83100999999741E-05 |
| Normal-vs-Age(41-60Yrs) |
2.11889999990333E-07 |
| Normal-vs-Age(61-80Yrs) |
1.31339999998037E-06 |
| Normal-vs-Age(81-100Yrs) |
3.767800E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.256800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.148400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.845000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.331200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.525200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.894000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.33430000381907E-08 |
| Classical-VS-Follicular |
5.8291000004651E-07 |
| Classical-VS-Other |
6.680200E-02 |
| Classical-VS-Normal |
2.0993999982899E-08 |
| Tall-VS-Follicular |
1.63424829224823E-12 |
| Tall-VS-Other |
1.445560E-01 |
| Tall-VS-Normal |
4.55191440096314E-15 |
| Follicular-VS-Other |
5.70060000000261E-05 |
| Follicular-VS-Normal |
2.024800E-01 |
| Other-VS-Normal |
1.73989999996405E-06 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.563900E-04 |
| Normal-vs-N1 |
1.49790180259401E-11 |
| N0-vs-N1 |
1.37749999995496E-06 |
|
|
